Tags

Type your tag names separated by a space and hit enter

Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
Rheumatology (Oxford). 2016 Nov; 55(11):1946-1953.R

Abstract

OBJECTIVES

To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission.

METHODS

Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial was a double-blind, randomised controlled trial of IFX in biologic-naïve patients with early, active axial SpA. Patients were randomised (2:1) to receive 28 weeks of treatment with i.v. IFX 5 mg/kg (weeks 0, 2, 6, 12, 18 and 24) + NPX 1000 mg/day or i.v. placebo (PBO) + NPX 1000 mg/day. The current post hoc analysis evaluated outcomes in patients who did or did not meet modified New York radiographic criteria for AS.

RESULTS

The analysis included 94 patients who met AS criteria and 56 with non-radiographic axial SpA (nr-axSpA). At week 28, Assessment of SpondyloArthritis international Society (ASAS) partial remission was greater with IFX + NPX than PBO + NPX for both the AS group (70.5 vs 33.3%, respectively) and the nr-axSpA group (50.0 vs 37.5%, respectively). A similar pattern occurred with several efficacy measures. Larger treatment effects occurred in the AS group than the nr-axSpA group, possibly due to baseline differences in disease characteristics. Multivariable analyses identified the type of treatment, age and HLA-B27 status as predictors of ASAS partial remission in the total study population. MRI sacroiliac joint scores were associated with partial remission during IFX + NPX treatment.

CONCLUSION

Patients with AS had greater partial remission with IFX + NSAID than NSAID therapy alone; patients with nr-axSpA had a smaller treatment effect. Baseline disease characteristics and age were associated with partial remission with IFX therapy.

Authors+Show Affiliations

Department of Gastroenterology, Infectiology, and Rheumatology, Charité, University Medicine Berlin, Berlin, Germany joachim.sieper@charite.de.Department of Gastroenterology, Infectiology, and Rheumatology, Charité, University Medicine Berlin, Berlin, Germany.Department of Rheumatology, REUMA Instituut, Hasselt, Belgium.Department Rheumatology and Clinical Immunology, Schön-Klinik, Hamburg, Germany.Department of Rheumatology, Kazan State Medical University, Kazan, Russia.Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University of Korea.Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.Division of Rheumatology, Department of Internal Medicine.Department of Biostatistics, Merck & Co, Kenilworth, NJ, USA.Department of Immunology, MSD Italy, Global Medical Affairs, Rome, Italy.Department of Clinical Research, Merck & Co, Kenilworth, NJ, USA.Department of Medical Affairs, MSD Belgium, Brussels, Belgium.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

27411482

Citation

Sieper, Joachim, et al. "Partial Remission in Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Treatment With Infliximab Plus Naproxen or Naproxen Alone: Associations Between Partial Remission and Baseline Disease Characteristics." Rheumatology (Oxford, England), vol. 55, no. 11, 2016, pp. 1946-1953.
Sieper J, Rudwaleit M, Lenaerts J, et al. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Rheumatology (Oxford). 2016;55(11):1946-1953.
Sieper, J., Rudwaleit, M., Lenaerts, J., Wollenhaupt, J., Myasoutova, L., Park, S. H., Song, Y. W., Yao, R., Huyck, S., Govoni, M., Chitkara, D., & Vastesaeger, N. (2016). Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Rheumatology (Oxford, England), 55(11), 1946-1953.
Sieper J, et al. Partial Remission in Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Treatment With Infliximab Plus Naproxen or Naproxen Alone: Associations Between Partial Remission and Baseline Disease Characteristics. Rheumatology (Oxford). 2016;55(11):1946-1953. PubMed PMID: 27411482.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. AU - Sieper,Joachim, AU - Rudwaleit,Martin, AU - Lenaerts,Jan, AU - Wollenhaupt,Jürgen, AU - Myasoutova,Leysan, AU - Park,Sung-Hwan, AU - Song,Yeong W, AU - Yao,Ruji, AU - Huyck,Susan, AU - Govoni,Marinella, AU - Chitkara,Denesh, AU - Vastesaeger,Nathan, Y1 - 2016/07/13/ PY - 2015/08/31/received PY - 2016/04/22/revised PY - 2016/7/15/pubmed PY - 2019/3/21/medline PY - 2016/7/15/entrez KW - ankylosing spondylitis KW - axial spondyloarthritis KW - biological products KW - early disease KW - infliximab KW - remission induction KW - treatment outcome KW - tumour necrosis factor α SP - 1946 EP - 1953 JF - Rheumatology (Oxford, England) JO - Rheumatology (Oxford) VL - 55 IS - 11 N2 - OBJECTIVES: To evaluate partial remission during treatment with infliximab (IFX) + naproxen (NPX) vs NPX alone in patients from the two subgroups of SpA and explore baseline predictors of partial remission. METHODS: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial was a double-blind, randomised controlled trial of IFX in biologic-naïve patients with early, active axial SpA. Patients were randomised (2:1) to receive 28 weeks of treatment with i.v. IFX 5 mg/kg (weeks 0, 2, 6, 12, 18 and 24) + NPX 1000 mg/day or i.v. placebo (PBO) + NPX 1000 mg/day. The current post hoc analysis evaluated outcomes in patients who did or did not meet modified New York radiographic criteria for AS. RESULTS: The analysis included 94 patients who met AS criteria and 56 with non-radiographic axial SpA (nr-axSpA). At week 28, Assessment of SpondyloArthritis international Society (ASAS) partial remission was greater with IFX + NPX than PBO + NPX for both the AS group (70.5 vs 33.3%, respectively) and the nr-axSpA group (50.0 vs 37.5%, respectively). A similar pattern occurred with several efficacy measures. Larger treatment effects occurred in the AS group than the nr-axSpA group, possibly due to baseline differences in disease characteristics. Multivariable analyses identified the type of treatment, age and HLA-B27 status as predictors of ASAS partial remission in the total study population. MRI sacroiliac joint scores were associated with partial remission during IFX + NPX treatment. CONCLUSION: Patients with AS had greater partial remission with IFX + NSAID than NSAID therapy alone; patients with nr-axSpA had a smaller treatment effect. Baseline disease characteristics and age were associated with partial remission with IFX therapy. SN - 1462-0332 UR - https://www.unboundmedicine.com/medline/citation/27411482/Partial_remission_in_ankylosing_spondylitis_and_non_radiographic_axial_spondyloarthritis_in_treatment_with_infliximab_plus_naproxen_or_naproxen_alone:_associations_between_partial_remission_and_baseline_disease_characteristics_ L2 - https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kew230 DB - PRIME DP - Unbound Medicine ER -